Biotech News
Depemokimab accepted for review by the European Medicines Agency for use in asthma with type 2 inflammation and CRSwNP
If approved, depemokimab will be the first ultra-long-acting biologic with 6-month dosing.
Related news
GSKGSK plc2026-07-20 07:00 EST
European Medicines Agency accepts submission to update Bexsero label for 1-dose Meningitis B booster in 10+ year olds
GSKGSK plc2026-08-24 07:01 EST
Jemperli (dostarlimab) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancer
RVMDRevolution Medicines2026-07-22 20:05 EST
Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer
RVMDRevolution Medicines2026-07-07 13:24 EST
European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process
REGNRegeneron Pharmaceuticals2026-06-22 11:00 EST
Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
ENTAEnanta Pharmaceuticals2026-06-23 09:10 EST
Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus
COGTCogent Biosciences2026-06-12 12:01 EST
Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress
BNTXBioNTech2026-07-29 20:30 EST
European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
SANASana Biotechnology2026-07-01 13:00 EST
Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026
BCRXBioCryst Pharmaceuticals2026-06-12 11:00 EST
BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
GSK plc
Global Biopharmaceutical Portfolio GSK is a global biopharmaceutical company operating across Specialty Medicines, Vaccines, and General Medicines. Its commercial portfolio spans HIV, oncology, respiratory and immuno-inflammation, vaccines, and established medicines, supported by a growing late-stage pipeline and externally sourced...
Recent company news
GSKGSK plc2026-08-24 07:01 EST
Jemperli (dostarlimab) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancer
GSKGSK plc2026-08-24 07:00 EST
Hibsago (bepirovirsen) approved in Japan as first and only functional cure for chronic hepatitis B
GSKGSK plc2026-07-29 09:08 EST
Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026
GSKGSK plc2026-07-28 12:05 EST
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSKGSK plc2026-07-28 12:00 EST
GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026
Stock data
- Close
- 52.41 USD
- Market cap
- 98.26B USD
- Exchange
- NYSE
- Sector
- Vaccines, Biopharma, Gene Therapy, Antibody Drugs, Small Molecule Drugs, Nucleic Acid Drugs
- Location
- United States